NCT00879242View on ClinicalTrials.gov

Effect of Deferasirox on Patients With Cardiac MRI T2* < 20 Msec

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

February 28, 2009

Primary Completion Date

May 31, 2011

Conditions
Beta Thalassemia Transfusion Dependent
Interventions
DRUG

Deferasirox

Dispersible tables of 125, 250 and 500 mg at the dose of 30 mg/kg/day, oral administration.

Trial Locations (2)

Unknown

Novartis Investigative Site, Cagliari

Novartis Investigative Site, Orbassano

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY